Artwork

内容由GovCIO Media & Research and GovCIO Media提供。所有播客内容(包括剧集、图形和播客描述)均由 GovCIO Media & Research and GovCIO Media 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Cancer HealthCast: This AI Tool Could Predict a Patient's Response to Immunotherapy

36:13
 
分享
 

Manage episode 425406844 series 2430691
内容由GovCIO Media & Research and GovCIO Media提供。所有播客内容(包括剧集、图形和播客描述)均由 GovCIO Media & Research and GovCIO Media 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Artificial Intelligence is impacting two main areas of cancer research: image analysis and managing massive amounts of clinical data. The National Cancer Institute sees AI as a key capability in precision oncology.

Dr. Eytan Ruppin, chief of NCI’s Cancer Data Science Lab, recently published a study about a new AI tool researchers are implementing to foresee how a patient will respond to immunotherapy by providing an in-depth look at the clinical characteristics of the patient as well as the Tumor Mutational Burden (TMB).

Ruppin discusses the NCI/CCR Synthesis Clinical Trial expected to start this fall and shares details about how the research will impact the treatment of aggressive breast cancer.

  continue reading

248集单集

Artwork
icon分享
 
Manage episode 425406844 series 2430691
内容由GovCIO Media & Research and GovCIO Media提供。所有播客内容(包括剧集、图形和播客描述)均由 GovCIO Media & Research and GovCIO Media 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Artificial Intelligence is impacting two main areas of cancer research: image analysis and managing massive amounts of clinical data. The National Cancer Institute sees AI as a key capability in precision oncology.

Dr. Eytan Ruppin, chief of NCI’s Cancer Data Science Lab, recently published a study about a new AI tool researchers are implementing to foresee how a patient will respond to immunotherapy by providing an in-depth look at the clinical characteristics of the patient as well as the Tumor Mutational Burden (TMB).

Ruppin discusses the NCI/CCR Synthesis Clinical Trial expected to start this fall and shares details about how the research will impact the treatment of aggressive breast cancer.

  continue reading

248集单集

Tüm bölümler

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南